CRIS Current Research Information System

CIANI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.926
AS - Asia 5.661
EU - Europa 4.451
AF - Africa 512
SA - Sud America 228
OC - Oceania 6
Totale 16.784
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.840
IT - Italia 1.710
SG - Singapore 1.570
VN - Vietnam 1.516
CN - Cina 1.332
GB - Regno Unito 694
DE - Germania 494
HK - Hong Kong 410
SE - Svezia 286
IN - India 215
NL - Olanda 211
FR - Francia 209
BR - Brasile 154
IE - Irlanda 150
RU - Federazione Russa 137
BD - Bangladesh 136
SC - Seychelles 135
TG - Togo 134
KR - Corea 122
UA - Ucraina 120
CI - Costa d'Avorio 105
FI - Finlandia 82
CH - Svizzera 77
JP - Giappone 76
ZA - Sudafrica 73
JO - Giordania 53
CA - Canada 52
BG - Bulgaria 51
ES - Italia 45
EE - Estonia 40
PH - Filippine 40
TR - Turchia 39
NG - Nigeria 36
AR - Argentina 33
AT - Austria 33
ID - Indonesia 30
BE - Belgio 29
TH - Thailandia 21
MX - Messico 20
PL - Polonia 18
IR - Iran 17
TW - Taiwan 16
GR - Grecia 12
HR - Croazia 11
MY - Malesia 11
IQ - Iraq 10
DK - Danimarca 9
EC - Ecuador 9
PK - Pakistan 9
AE - Emirati Arabi Uniti 8
CL - Cile 7
SA - Arabia Saudita 7
VE - Venezuela 7
AU - Australia 6
CO - Colombia 6
MA - Marocco 6
PE - Perù 6
RO - Romania 6
CZ - Repubblica Ceca 5
LB - Libano 5
SM - San Marino 5
DZ - Algeria 4
NP - Nepal 4
PT - Portogallo 4
EG - Egitto 3
ET - Etiopia 3
KE - Kenya 3
MD - Moldavia 3
PY - Paraguay 3
UZ - Uzbekistan 3
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CD - Congo 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
GT - Guatemala 1
IS - Islanda 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MU - Mauritius 1
Totale 16.776
Salva come PNG Salva come JPEG
Città #
Singapore 1.169
Bologna 630
Ashburn 627
Chandler 543
Southend 504
Fairfield 503
Ho Chi Minh City 369
Hong Kong 368
Hanoi 335
Hefei 308
Santa Clara 304
San Jose 301
Houston 256
Wilmington 234
Woodbridge 227
Seattle 216
Ann Arbor 210
Cambridge 188
Beijing 167
Dublin 149
Dong Ket 144
Boardman 138
Princeton 137
Lomé 134
Dallas 120
Seoul 109
Abidjan 105
Council Bluffs 95
Los Angeles 91
Turin 77
Milan 76
Frankfurt am Main 74
Jacksonville 72
Lauterbourg 71
New York 67
Bern 65
Helsinki 63
Nanjing 59
Tokyo 57
Bristol 55
Padova 55
Westminster 55
Amman 52
Falls Church 50
Berlin 49
Sofia 49
Buffalo 48
Redmond 47
Rimini 42
Rome 42
Da Nang 37
Haiphong 37
San Diego 36
Trento 36
Bengaluru 34
Marano 34
Munich 32
Abeokuta 31
Amsterdam 30
Islington 29
Shenyang 29
Brussels 28
Changsha 28
Tianjin 26
Guangzhou 25
Jinan 24
Argelato 23
Saint Petersburg 23
Orem 22
Redondo Beach 22
Johannesburg 21
Toronto 21
Vienna 21
Chicago 20
Hải Dương 20
Shanghai 18
São Paulo 18
Florence 17
Modena 17
Mülheim 17
Nanchang 17
Biên Hòa 15
Bolzano 15
Bonn 15
Dearborn 15
Falkenstein 15
Hebei 15
Jakarta 15
Jerez De La Frontera 15
Pune 15
Redwood City 15
Wuhan 15
Bremen 14
Castel Maggiore 14
Istanbul 14
San Francisco 14
Des Moines 13
Mumbai 13
Naples 13
London 12
Totale 10.971
Salva come PNG Salva come JPEG
Nome #
Inhibition of microglia over-activation restores neuronal survival and maturation in a mouse model of CDKL5 deficiency disorder 398
Beneficial Antioxidant Effects of Coenzyme Q10 in In Vitro and In Vivo Models of CDKL5 Deficiency Disorder 357
Age-related cognitive and motor decline in a mouse model of CDKL5 deficiency disorder is associated with increased neuronal senescence and death 348
Characterization of Perinatal Stem Cell Spheroids for the Development of Cell Therapy Strategy 335
CDKL5 protein substitution therapy rescues neurological phenotypes of a mouse model of CDKL5 disorder 333
AR-A014418-based dual Glycogen Synthase Kinase 3β/Histone Deacetylase inhibitors as potential therapeutics for Alzheimer's disease 311
Cardiac Functional and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder 309
A GABAB receptor antagonist rescues functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder 295
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer’s Disease 294
Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder 293
Functional impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are ameliorated by a GABAB receptor antagonist 279
Expression of a Secretable, Cell-Penetrating CDKL5 Protein Enhances the Efficacy of Gene Therapy for CDKL5 Deficiency Disorder 255
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder 253
CDKL5 deficiency entails sleep apneas in mice 251
Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder 251
CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling (vol 29, pg 658, 2019) 250
Artificial protein and its applications 249
HDAC4: a key factor underlying brain developmental alterations in CDKL5 disorder 243
Increased DNA Damage and Apoptosis in CDKL5-Deficient Neurons 242
Treatment with a GSK-3β/HDAC Dual Inhibitor Restores Neuronal Survival and Maturation in an In Vitro and In Vivo Model of CDKL5 Deficiency Disorder 241
Dietary restriction differentially protects from neurodegeneration in animal models of excitotoxicity. 234
Treatment with FRAX486 rescues neurobehavioral and metabolic alterations in a female mouse model of CDKL5 deficiency disorder 229
Lithium Restores Age Related Olfactory Impairment in the Ts65Dn Mouse Model of Down Syndrome 224
Age-related impairment of olfactory bulb neurogenesis in the Ts65Dn mouse model of Down syndrome 220
Epigallocatechin gallate: A useful therapy for cognitive disability in Down syndrome? 216
Cyclic AMP-mediated regulation of transcription factor Lot1 expression in cerebellar granule cells. 215
The amyloid precursor protein (APP) triplicated gene impairs neuronal precursor differentiation and neurite development through two different domains in the Ts65Dn mouse model for down syndrome. 215
CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells 214
Early Pharmacotherapy with Fluoxetine Rescues Dendritic Pathology in the Ts65Dn Mouse Model of Down Syndrome 214
Functional and structural impairments in the perirhinal cortex of a mouse model of CDKL5 deficiency disorder are rescued by a TrkB agonist 210
APP-dependent alteration of GSK3β activity impairs neurogenesis in the Ts65Dn mouse model of Down syndrome. 207
Treatment with the GSK3-beta inhibitor Tideglusib improves hippocampal development and memory performance in juvenile, but not adult, Cdkl5 knockout mice 207
Neurochemical correlates of nicotine neurotoxicity on rat habenulo-interpeduncular cholinergic neurons. 204
Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome 204
Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder 204
Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder 203
Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder 201
Postnatal neurogenesis in the dentate gyrus of the guinea pig 198
Widespread impairment of cell proliferation in the neonate Ts65Dn mouse, a model for Down syndrome. 198
APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. 198
Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice 197
Voluntary Running Improves Behavioral and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder 188
Cell cycle elongation impairs proliferation of cerebellar granule cell precursors in the Ts65Dn Mouse, an animal model for Down syndrome. 186
Choline acetyltransferase activity at different ages in brain of Ts65Dn mice, an animal model for Down's syndrome and related neurodegenerative diseases. 185
Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome 184
Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome 182
Lactic acid bacteria as microbial cell factories for the in vivo delivery of therapeutic proteins as secretable TAT fusion products 182
Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. 179
Sex differences in the stereological parameters of the hippocampal dentate gyrus of the guinea pig before puberty 177
Sex differences in the hilar mossy cells of the guinea-pig before puberty. 175
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo 172
Design, synthesis and pharmacological evaluation of multitarget GPR40 agonists/HDAC6 inhibitors for Alzheimer's disease 169
Early-occurring proliferation defects in peripheral tissues of the Ts65Dn mouse model of Down syndrome are associated with patched1 over expression 169
Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome 169
Impact of environmental enrichment on neurogenesis in the dentate gyrus during the early postnatal period. 168
Characterisation of sleep apneas and respiratory circuitry in mice lacking CDKL5 165
Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. 165
Proliferation of cerebellar precursor cells is negatively regulated by nitric oxide in newborn rat. 164
Timing of therapies for downsyndrome: The sooner, the better 163
Effect of early isolation on signal transfer in the entorhinal cortex-dentate-hippocampal system 162
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model. 162
The place of choline acetyltransferase activity measurement in the "cholinergic hypothesis" of neurodegenerative diseases 161
Mapping pathological phenotypes in a mouse model of CDKL5 disorder. 157
CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/GSK-3{beta}/{beta}-catenin signaling 157
Lot1 is a key element of the pituitary adenylate cyclase-activating polypeptide (PACAP)/cyclic AMP pathway that negatively regulates neuronal precursor proliferation. 153
Widespread proliferation impairment and hypocellularity in the cerebellum of fetuses with Down syndrome. 151
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome 149
Is it possible to improve neurodevelopmental abnormalities in Down syndrome? 142
Updating the dual role of brain nitric oxide in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. 139
Adult-Onset Deletion of CDKL5 in Forebrain Glutamatergic Neurons Impairs Synaptic Integrity and Behavior in Mice 138
Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig. 137
Site-specific abnormalities in the visual system of a mouse model of CDKL5 deficiency disorder 136
Heterozygous CDKL5 Knockout Female Mice Are a Valuable Animal Model for CDKL5 Disorder 136
null 130
Role of nitric oxide in the regulation of neuronal proliferation, survival and differentiation. 129
Effects of a ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic in an in vitro and in vivo model of CDKL5 deficiency disorder 128
Neurogenesis impairment and increased cell death reduce total neuron number in the hippocampal region of fetuses with Down syndrome 125
Lithium restores neurogenesis in the subventricular zone of the Ts65Dn mouse, a model for Down sindrome 117
TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF 115
Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome 113
Safety and efficacy of Igk-TATk-CDKL5 gene therapy in mosaic CDKL5 deficiency 103
null 100
null 97
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. 96
Autistic-relevant behavioral phenotypes of a mouse model of cyclin-dependent kinase-like 5 deficiency disorder 78
Sex differences in the hippocampal dentate gyrus of the guinea-pig before puberty 78
A cross-correction gene therapy approach for CDKL5 deficiency disorder improves the pathological phenotype of CDD patient-derived cortical organoids 56
Effects of gestational or neonatal treatment with alpha-difluoromethylornithine on ornithine decarboxylase and polyamines in developing rat brain and on adult rat neurochemistry 50
Sex differences in the hilar mossy cells of the guinea-pig before puberty 47
Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: Implication for a survival role of nitric oxide 46
Totale 17.029
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.499
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.499
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021342 0 0 0 0 0 0 0 0 0 0 0 342
2021/20221.475 99 71 117 117 135 102 62 80 71 107 261 253
2022/20232.213 173 366 105 260 162 196 55 125 365 51 166 189
2023/2024797 58 83 37 85 49 135 88 70 50 40 42 60
2024/20252.529 139 289 183 211 397 161 154 95 90 228 142 440
2025/20266.450 502 840 526 475 689 306 766 249 1.113 390 348 246
Totale 17.029